Click here for slides on this topic


Sulfonylureas

A class of oral antihyperglycemic agents that stimulates insulin secretion from the pancreatic beta-cells.
The following content matched the glossary term: Sulfonylureas

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

NDEI.org Expert Commentary Silvio E. Inzucchi MD on Type 2 Diabetes Treatment Recommendations

Top

EXPERT COMMENTARY New Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes   Silvio E. Inzucchi, MD  Weight loss remains a great challenge for our patients, especially those with type 2 diabetes. While lifestyle

AACE 2015 guidelines Glycemic Control Algorithm

Top

AACE’s glycemic control algorithm outlines pharmacologic treatment options for diabetes from the 2015 AACE guidelines 

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial

Top

Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9):2522-2532.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Sulfonylureas Slides Found: 42
Sulfonylureas: Efficacy
Sulfonylureas: Prescribing Considerations
Effects of Antidiabetic Agents on Weight
Sulfonylureas: Efficacy
Sulfonylureas: Prescribing Considerations
Exenatide: Clinical Pharmacology
Adverse Events Associated With Thiazolidinedione Treatment
Exenatide: Effect on the Beta-Cell
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
ACCORD: Study Design
ADVANCE: Study Design
Alogliptin and Glyburide Combination Therapy: A1C
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean A1C Change
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: A1C Target at Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean Body Weight Change
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
Sulfonylureas Metformin Cancer Risk Type 2 Diabetes | NDEI
Cancer Incidence Metformin Sulfonylureas Type 2 Diabetes | NDEI
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI